提醒：专家访问-巴克莱主办：关键意见领袖电话会议，聚焦肾、膀胱和前列腺癌的新兴疗法：美国东部时间5月28日（明天）下午12点

Restricted - External Key topics of discussion will include the following:•RCUS:Casdatifan (HIF-2a inhibitor) in RCC••EXEL:Cabozantinib andzanzalintinib in RCC••BCYC: zelenectide pevedotin (Nectin-4) in urothelial carcinoma••MGNX:Lorigerlimab (PD-1xCTLA-4) and MGC026 (TOP1i B7-H3 ADC) in mCRPC•Meet the SpeakerPedro Barata MDis an Associate Professor at Case Western Reserve University School ofMedicine and Miggo Family Endowment Chair in Clinical Research at the UniversityHospitals Seidman Cancer Center, University Hospitals in Cleveland OH. He is BoardCertified in Internal Medicine, Medical Oncologist with a focus in genitourinary tumors andclinical trials. He earned his medical degree from the New University of Lisbon in 2009 andcompleted his medical oncology training in 2016.Aftercompletion of his fellowship, he wasinvited to join the genitourinary group at Taussig Cancer Center, where he worked as aclinical fellow in genitourinary malignancies.Afterspending four years at Tulane Universityleading the non-prostate program, Dr. Barata joined Case Comprehensive Cancer Center asthe new leader of the clinical and translational research of advanced GU tumors.Meet the AnalystPeter Lawson, DPhil (Oxon) is a Managing Director andEquity Research Analyst covering the U.S. Small and MidCap Biotechnology sector, with over 15 years of sell-sideresearch experience. Before joining Barclays in December2019, Peter spent over four years at SunTrust RobinsonHumphrey as a Managing Director and Senior EquityResearch Analyst covering the Biotechnology sector. Peterserved as Executive Director and Senior Equity ResearchAnalyst covering the Biotechnology sector at MizuhoSecurities USA until September 2015, as well as ManagingDirector and Equity Analyst covering the Life Science Toolssector at Thomas Weisel Partners until July 2010. Petergraduated from the University of Oxford with a DPhil inBiochemistry and holds a BSc in Physiology fromUniversity College London.U.S. Small & Mid Cap Biotechnology View Analyst Page BCI, USThis event is intended for Barclays institutional investor clients only. This event is strictly and solelyfor the benefit of the intended recipients. Please do not forward this invitation to any other partywithout written consent from Barclays Research. Barclays' Investment Bankers are permitted toattend this event. Participant comments are not for attribution.If your firm is in-scope for research unbundling under MiFID II and you require further informationregarding pricing to participate in this Barclays Research content event, please contact your salesrepresentative.Barclays Events Terms of Service | Barclays Events Privacy NoticeDisclaimer:BARCLAYSThis communication has been prepared by Barclays.“Barclays” means any entity within the Barclays Group of companies, where “Barclays Group” meansBarclays Bank PLC, Barclays PLC and any of their subsidiaries,affiliates,ultimate holding companyand any subsidiaries oraffiliatesof such holding company.CONFLICTS OF INTERESTBARCLAYS IS A FULL SERVICE INVESTMENT BANK. In the normal course ofofferinginvestment bankingproducts and services to clients, Barclays may act in several capacities (including issuer, marketmaker and/or liquidity provider, underwriter, distributor, index sponsor, swap counterparty andcalculation agent) simultaneously with respect to a product, giving rise to potential conflicts ofinterest which may impact the performance of a product.BARCLAYS POSITIONSBarclays may at any time acquire, hold or dispose of long or short positions (including hedging andtrading positions) and trade or otherwiseeffecttransactions for their own account or the account oftheir customers in the products referred to herein which may impact the performance of a product.FOR INFORMATION ONLYTHIS DOCUMENT IS PROVIDED FOR INFORMATION PURPOSES ONLY AND IT IS SUBJECT TO CHANGE.This information has been prepared by the Research Department within the Investment Bank ofBarclays. The information, analytic tools, and/or models referenced herein (and any reports or resultsderived from their use) are intended for informational purposes only. Barclays has no obligation toupdate this information and may cease provision of this information at any time and without notice.NO OFFERBarclays is notofferingto sell or seekingoffersto buy any product or enter into any transaction. Anyofferor entry into any transaction requires Barclays’ subsequent formal agreement which will besubject to internal approvals and execution of binding transaction documents. The productsmentioned may not be eligible for sale in some states or countries, nor suitable for all types ofinvestors. Without limitation to the foregoing, any transaction may also be subject to review byBarclays Group against its published Tax Principles.NO LIABILITYNeither Barclays nor any of its directors,officers,employees, representatives or agents, accepts anyliability whatsoever for any direct, indirect or consequential losses (in contract, to